ClinicalTrials.gg
CompletedNCT06542874Updated Oct 2, 2026

A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes

A Phase 2 interventional study of NNC0487-0111 subcutanous and Placebo (NNC0487-0111 subcutanous) in Type 2 Diabetes (T2D), sponsored by Novo Nordisk A/S. Completed at 137 sites in 11 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2025, 1 year 1 month ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Sep 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
448
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S — 25 open to participants now, 29 under way, 11 of them phase 3. Diabetes Mellitus, Type 2 · Novo Nordisk A/S.

Enrollment
114th of 428
448 · median 209
Started
2024
with 25 others
Phase 2
37 of 643
2 open now
Registered
606th of 643
by date

Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 114th largest by enrollment of the 428 interventional ones that give a count, is one of 26 that started in 2024, is one of 37 in phase 2, and was the 606th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

25 of the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

20 more — sign in →

By country, each count listing its studies:

All 25 open studies →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, or all of them as a file.
02

Study summary

The study will look at how well different doses of a new medicine called NNC0487-0111 help lower the blood sugar and body weight in people with type 2 diabetes. NNC0487-0111 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Participants will either get NNC0487-0111, which is given as tablets or as injections, or placebo. Which treatment the participant get is decided by chance.The study will last for about 43 weeks.

03

Conditions studied

  • Type 2 Diabetes (T2D)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, aged 18-75 years (both inclusive) at the time of signing the .
  • Diagnosed with type 2 diabetes mellitus greater or equal to 180 days before screening.
  • Stable daily dose(s) greater or equal to 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator: metformin with or without SGLT2 inhibitor.
  • of 7.0-10.0 procent (53-86 mmol/mol) (both inclusive) as assessed by central laboratory at screening.
  • between greater or equal to 23.0 and below 50.0 kg/m\^2.
  • Able and willing to adhere to the protocol including wearing a continuous glucose monitoring (CGM) device provided for the study, as judged by the investigator.

Exclusion criteria

Exclusion Criteria:

  • Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
  • Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
448 participants (actual)

Study arms

  • Placebo comparator
    Placebo subcutaneous

    Placebo for subcutaneous treatment

    Drug: Placebo (NNC0487-0111 subcutanous)

  • Experimental
    NNC0487-0111 subcutaneous dose 1

    NNC0487-0111 subcutaneous dose 1 treatment

    Drug: NNC0487-0111 subcutanous

  • Experimental
    NNC0487-0111 subcutaneous dose 2

    NNC0487-0111 subcutaneous dose 2 treatment

    Drug: NNC0487-0111 subcutanous

  • Experimental
    NNC0487-0111 subcutaneous dose 3

    NNC0487-0111 subcutaneous dose 3 treatment

    Drug: NNC0487-0111 subcutanous

  • Experimental
    NNC0487-0111 subcutaneous dose 4

    NNC0487-0111 subcutaneous dose 4 treatment

    Drug: NNC0487-0111 subcutanous

  • Experimental
    NNC0487-0111 subcutaneous dose 5

    NNC0487-0111 subcutaneous dose 5 treatment

    Drug: NNC0487-0111 subcutanous

  • Experimental
    NNC0487-0111 subcutaneous dose 6

    NNC0487-0111 subcutaneous dose 6 treatment

    Drug: NNC0487-0111 subcutanous

  • Placebo comparator
    Placebo oral

    Placebo for oral treatment

    Drug: Placebo (NNC0487-0111 oral)

  • Experimental
    NNC0487-0111 oral dose 1

    NNC0487-0111 oral dose 1 treatment

    Drug: NNC0487-0111 oral

  • Experimental
    NNC0487-0111 oral dose 2

    NNC0487-0111 oral dose 2 treatment

    Drug: NNC0487-0111 oral

  • Experimental
    NNC0487-0111 oral dose 3

    NNC0487-0111 oral dose 3 treatment

    Drug: NNC0487-0111 oral

Interventions

  • NNC0487-0111 administered subcutanously (under the skin)

  • DrugPlacebo (NNC0487-0111 subcutanous)

    NNC0487-0111 placebo administered subcutanously (under the skin)

  • NNC0487-0111 administered orally (in the mouth)

  • DrugPlacebo (NNC0487-0111 oral)

    NNC0487-0111 placebo administered orally (in the mouth)

06

What researchers measure

Primary outcomes

  1. Change in HbA1c

    percent point

    Time frame: From baseline (week 0) to end of treatment (week 36)

Secondary outcomes

  1. Relative change in body weight

    percent

    Time frame: From baseline (week 0) to end of treatment (week 36)

  2. Change in body weight

    kg

    Time frame: From baseline (week 0) to end of treatment (week 36)

  3. Change in fasting plasma glucose (FPG)

    mmol/L

    Time frame: From baseline (week 0) to end of treatment (week 36)

  4. CGM: Change in time in range (TIR) 3.9-10.0 mmol/L (70-180 mg/dL)

    percent points

    Time frame: From baseline (week 0) to end of treatment (week 36)

  5. Change in body mass index (BMI)

    kg/m\^2

    Time frame: From baseline (week 0) to end of treatment (week 36)

  6. Change in waist circumference

    cm

    Time frame: From baseline (week 0) to end of treatment (week 36)

  7. Change in systolic blood pressure (SBP)

    mmHg

    Time frame: From baseline (week 0) to end of treatment (week 36)

  8. Change in average 24-hour systolic blood pressure (SBP)

    mmHg

    Time frame: From baseline (week 0) to end of treatment (week 36)

  9. Change in high sensitivity C-Reactive Protein (hsCRP)

    Ratio to baseline

    Time frame: From baseline (week 0) to end of treatment (week 36)

  10. Change in total cholesterol

    Ratio to baseline

    Time frame: From baseline (week 0) to end of treatment (week 36)

  11. Change in high-density lipoprotein (HDL) cholesterol

    Ratio to baseline

    Time frame: From baseline (week 0) to end of treatment (week 36)

  12. Change in low-density lipoprotein (LDL) cholesterol

    Ratio to baseline

    Time frame: From baseline (week 0) to end of treatment (week 36)

  13. Change in triglycerides

    Ratio to baseline

    Time frame: From baseline (week 0) to end of treatment (week 36)

  14. Number of adverse events

    Count of events

    Time frame: From baseline (week 0) to end of study (week 40)

  15. Change in Urinary Albumin/Creatinine Ratio (UACR)

    Ratio to baseline

    Time frame: From baseline (week 0) to end of treatment (week 36)

  16. Participant without macroalbuminuria (UACR < 300 mg/g) at baseline (week 0) developing (yes/no) new onset of macroalbuminuria (UACR ≥ 300 mg/g)

    Count of participant

    Time frame: At end of treatment (week 36)

  17. Change in eGFR creatinine- and cystatin C based CKD-EPI

    mL/min/1.73 m\^2

    Time frame: From baseline (week 0) to end of treatment (week 36)

07

Study locations

137 sites
  • Uni of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Velocity Clin Research LA
    Los Angeles, California 90057, United States
  • Southern Cal Clinical Research
    Santa Ana, California 92701, United States
  • Chase Medical Research LLC
    Waterbury, Connecticut 06708, United States
  • Fleming Island Ctr for Clin Res
    Fleming Island, Florida 32003, United States
  • Encore Medical Research LLC
    Hollywood, Florida 33024, United States
  • South Broward Research LLC
    Miramar, Florida 33027, United States
  • Florida Inst For Clin Res
    Orlando, Florida 32825, United States
  • Florida Institute for Clinical research
    Orlando, Florida 32825, United States
  • Cedar-Crosse Research Center
    Chicago, Illinois 60607, United States
  • Cotton O'Neil Clinical Research Center
    Topeka, Kansas 66606, United States
  • Advanced Internal Medicine, PLLC
    Paducah, Kentucky 42001, United States
  • Medstar Research Institute_Hyattsville
    Hyattsville, Maryland 20782, United States
  • MD Medical Research
    Oxon Hill, Maryland 20745, United States
  • Brigham & Women's Hospital
    Boston, Massachusetts 02115, United States
  • ActivMed Practice & Research LLC
    Methuen, Massachusetts 01844, United States
  • Arcturus HC PLC Troy Med Res
    Troy, Michigan 48098, United States
  • Arcturus Healthcare, PLC
    Troy, Michigan 48098, United States
  • Clinical Research Professionals
    Chesterfield, Missouri 63005, United States
  • StudyMetrix Research LLC
    City of Saint Peters, Missouri 63303, United States
  • AMC Community Endocrinology
    Albany, New York 12203, United States
  • Centricity Rsrch MHCity Multi
    Morehead City, North Carolina 28557, United States
  • Piedmont Healthcare/Research
    Statesville, North Carolina 28625, United States
  • Lillestol Research LLC
    Fargo, North Dakota 58104, United States
  • Plains Clinical Research Center, LLC_Fargo
    Fargo, North Dakota 58104, United States
  • Alliance for Multispec Res
    Norman, Oklahoma 73069, United States
  • Jefferson Endocrinology Assocs
    Philadelphia, Pennsylvania 19107-6810, United States
  • Preferred Primary Care Physicians_Pittsburgh
    Pittsburgh, Pennsylvania 15236, United States
  • Health Concepts
    Rapid City, South Dakota 57702, United States
  • Holston Medical Group
    Kingsport, Tennessee 37660, United States
  • Clinical Research Associates
    Nashville, Tennessee 37203, United States
  • MidState Endocrine Associates
    Nashville, Tennessee 37203, United States
  • Velocity Clinical Res-Dallas
    Dallas, Texas 75230, United States
  • Victorium Clinical Research
    Houston, Texas 77024, United States
  • Synergy Groups Medical
    Houston, Texas 77061, United States
  • PlanIt Research, PLLC
    Houston, Texas 77079, United States
  • Radiance Clinical Research
    Lampasas, Texas 76550, United States
  • Tekton Research
    McKinney, Texas 75069, United States
  • Hillcrest Family Health Center
    Waco, Texas 76708, United States
  • Individual Practice For Specialized Outpatient Medical Care Doctor Miglena Rizova Ltd.
    Kyustendil, 2500, Bulgaria
  • IPSOMC Dr. Miglena Rizova Ltd.
    Kyustendil, 2500, Bulgaria
  • UMHAT "Kaspela", Depart. Endocrinology and Metab. Diseases
    Plovdiv, 4001, Bulgaria
  • UMHAT Kaspela EOOD, Endocrinology and Metabolic Diseases Clinic
    Plovdiv, 4001, Bulgaria
  • DCC Sveti Georgi EOOD
    Plovdiv, 4002, Bulgaria
  • Diagnostic-Consultative Centre "Sveti Georgi" Eood
    Plovdiv, 4002, Bulgaria
  • Medical centre Regina Life Clinic EOOD
    Sofia, 1000, Bulgaria
  • UMHAT "Aleksandrovska"
    Sofia, 1431, Bulgaria
  • UMHAT Aleksandrovska EAD, Densitometry and Bone Metabolic Diseases
    Sofia, 1431, Bulgaria
  • USHATE "Akad. Ivan Penchev" Second Clinic of Endocrinology
    Sofia, 1431, Bulgaria
  • USHATE Akad. Ivan Penchev EAD, Second Clinic of Endocrinology
    Sofia, 1431, Bulgaria
  • AIPSMC Dr. Artin Magardichyan EOOD
    Varna, 9020, Bulgaria
  • Poliklinika Solmed
    Zagreb, City of Zagreb 10000, Croatia
  • Clinical Hospital Centre Rijeka_Endocrinology
    Rijeka, Primorje-Gorski Kotar County 51 000, Croatia
  • KBC Rijeka, Endokrinologija
    Rijeka, Primorje-Gorski Kotar County 51 000, Croatia
  • Opca bolnica Karlovac
    Karlovac, 47000, Croatia
  • Specijalna bolnica Krapinske Toplice - Endokrinologija
    Krapinske Toplice, 49217, Croatia
  • Specijalna Bolnica za medicinsku rehabilitaciju Krapinske Toplice_Endocrinology
    Krapinske Toplice, 49217, Croatia
  • Klinicki bolnicki centar Osijek_Endocrinology
    Osijek, 31 000, Croatia
  • Klinicki bolnicki centar Osijek
    Osijek, 31 000, Croatia
  • Opca bolnica Varazdin_Endocrinology
    Varaždin, 42 000, Croatia
  • Opca bolnica Varazdin
    Varaždin, 42 000, Croatia
  • Zentrum fuer klinische Studien Suedbrandenburg GmbH
    Elsterwerda, 04910, Germany
  • Zentrum für klinische Studien Südbrandenburg GmbH
    Elsterwerda, 04910, Germany
  • InnoDiab Forschung GmbH
    Essen, 45136, Germany
  • Wendisch - Dahl Hamburg - DZHW
    Hamburg, 22607, Germany
  • Wendisch/Dahl Hamburg
    Hamburg, 22607, Germany
  • Institut für Diabetesforschung GmbH Münster - Dr. med. Rose
    Münster, 48145, Germany
  • RED-Institut für medizinische Forschung und Fortbildung GmbH
    Oldenburg in Holstein, 23758, Germany
  • Iatriko Psychicou Private Clinic
    Athens, 115 25, Greece
  • U.G.H of Athens "Attikon"
    Athens, 12462, Greece
  • "Laiko" General Hospital of Athens
    Goudi/Athens, 11527, Greece
  • EUROMEDICA Gen Clinic The/ki, Endocrin,Metabolism,Diabetes
    Thessaloniki, 54645, Greece
  • 424 Military General Training Hospital - 2nd Department of Internal Medicine
    Thessaloniki, 564 29, Greece
  • 424 Military General Training Hospital
    Thessaloniki, 564 29, Greece
  • "Thermi" Private Hosital
    Thessaloniki, 57001, Greece
  • EUROMEDICA Gen Clinic The/ki, Endocrin,Metabolism,Diabetes
    Thessaloniki, GR-54643, Greece
  • "Thermi" Private Hosital
    Thessaloniki, GR-57001, Greece
  • Debreceni Egyetem
    Debrecen, Hajdú-Bihar 4032, Hungary
  • Bajcsy-Zsilinszky Kórház
    Budapest, 1106, Hungary
  • MH Egészségügyi Központ
    Budapest, 1134, Hungary
  • Debreceni Egyetem
    Debrecen, 4031, Hungary
  • Debreceni Egyetem
    Debrecen, H-4031, Hungary
  • Debreceni Egyetem
    Debrecen, H-4032, Hungary
  • Békés Megyei Központi Kórház
    Gyula, 5700, Hungary
  • Somogy Vármegyei Kaposi Mór Oktató Kórház
    Kaposvár, 7400, Hungary
  • Somogy Vármegyei Kaposi Mór Oktató Kórház
    Kaposvár, H-7400, Hungary
  • Heiwadai Hospital_Internal Medicine
    Miyazaki, Miyazaki 880-0034, Japan
  • Heiwadai Hospital
    Miyazaki, Miyazaki 880-0034, Japan
  • TOSAKI Clinic for Diabetes and Endocrinology_Diabetes and Endocrinology
    Aichi, 468-0009, Japan
  • Tokuyama clinic_Diabetic internal medicine
    Chiba, 261-0004, Japan
  • Tokuyama clinic
    Chiba, 261-0004, Japan
  • Akaicho Clinic
    Chiba-shi, Chiba, 260-0804, Japan
  • Naka Kinen Clinic_Internal medicine
    Ibaraki, 311-0113, Japan
  • Naka Kinen Clinic
    Ibaraki, 311-0113, Japan
  • Tokyo-Eki Center-building Clinic_Internal Medicine
    Tokyo, 103-0027, Japan
  • Tokyo-Eki Center-building Clinic
    Tokyo, 103-0027, Japan
  • Fukuwa Clinic_Internal Medicine
    Tokyo, 104-0031, Japan
  • Fukuwa Clinic
    Tokyo, 104-0031, Japan
  • Niepubliczny Zaklad Opieki Zdrowotnej Przychodnia Specjalistyczna A Wittek H Rudzki Sp. j.
    Ruda Śląska, Gornoslaskie 41-709, Poland
  • Med. Cent. Diabet. Endo. Metabol. DIAB-ENDO-MET
    Krakow, Lesser Poland Voivodeship 31-261, Poland

Showing the first 100 of 137 sites across 11 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Mora P, Aroda VR, Asong M, Bluher M, Heftdal LD, Carlander AF, Vilsen LN, Rosenstock J. Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. Lancet. 2026 Jul 30:S0140-6736(26)01248-1. doi: 10.1016/S0140-6736(26)01248-1. Online ahead of print. PubMed 42532080 ↗
  • Mora P, Aroda VR, Asong M, Bluher M, Carlander AF, Kaltoft M, Vilsen LN, Rosenstock J. Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. Lancet. 2026 Jul 30:S0140-6736(26)01247-X. doi: 10.1016/S0140-6736(26)01247-X. Online ahead of print. PubMed 42532079 ↗

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Oct 2025, 13 months.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 13 months is close to that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2024
First posted
Aug 7, 2024
StartActual
Aug 7, 2024
Primary completionActual
Oct 1, 2025
CompletionActual
Oct 24, 2025
Results delay requested
Sep 30, 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers, verification date and registry dates
1 update, last Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Minor edits only
    + 3 other changes: identifiers, verification date and registry dates

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06542874
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Aug 7, 2024
Start date
Aug 7, 2024
Primary completion
Oct 1, 2025
Completion
Oct 24, 2025
Last update
Oct 2, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NNC0487-0111

Start the discussion